麻杏二三汤对哮喘大鼠肺组织TGF-β1和ET-1表达的影响

The Effect of Maxingersantang Decoction on the Expression of TGF-β1 and ET-1 of Lung Tissues in Asthmatic Rats

目的:探讨麻杏二三汤对哮喘大鼠气肺组织TGF-β1和ET-1表达影响。方法:40只SD大鼠随机分为空白组、模型组、麻杏二三汤组、地塞米松组,各组共10只。除空白组,采用鸡卵清蛋白(Ovalbumin,OVA)+氢氧化铝干粉联合致敏法造模2周,之后激发哮喘发作、分组给药,激发20 d后处死大鼠,观察体重、肺系数、病理组织学变化和采用酶联免疫吸附试验(ELIEA)法检测肺组织TGF-β1和ET-1含量。结果:1)与空白组比,模型组大鼠体重较小、肺系数增大、支气管管壁和支气管平滑肌厚度增高以及肺组织TGF-β1、ET-1表达升高(P<0.05)。2)与模型组比,两个药物干预组均可见肺系数、支气管壁和平滑肌厚度以及肺组织TGF-β1、ET-1含量显著降低;麻杏二三汤组在降低支气管管壁和支气管平滑肌厚度上效果更佳(P<0.05)。结论:气道重塑构建中TGF-β1、ET-1表达与其成正相关;麻杏二三汤可以延缓气道重塑进而治疗哮喘,其机制可能与下调TGF-β1、ET-1含量有关。

Objective：To explore expression changes of TGF-βI and ET-1 of lung tissues in asthmatic rats after the effect of Max- ingersantang decoction. Methods： Forty Sprague-Dawley （SD） rats were randomly divided into 4 groups： normal group, model group, Maxingersantang decoction group, and dexamethasone group, 10 rats in each group. Except the normal group, Rats were sensitized by ovalbumin （OVA） and Aluminum hydroxide powder to establish asthmatic model for two weeks, then different medi- cine were used respectively for intervention after the first sensitization. After 20 days of treatment, the rats were killed and lung tis- sues were taken to observe the weight, the lung coefficient as well as histopathological changes and ELIEA method was used to measure the level of TGF-β1 and ET-1. Results： 1 ） Compared with the normal group, the model group＇ s rats＇ weight was less while the lung coefficient, the thickness of airway wall and smooth muscle and the levels of TGF-β1 and ET-1 increased （P 〈 0. 05）. 2）Compared with the model group, lung coefficient, the thickness of airway wall and smooth muscle, the levels of TGF-β1 and ET-1 all decreased significantly for the two drug intervention groups （ P 〈 0. 05 ）. Maxingersantang decoction had better effect on decreasing the thickness of airway wall and smooth muscle. Conclusion： There is positive correlation between TGF-β1, ET-1 and airway remodeling. Maxingersantang decoction can delay the airway remodeling in treating asthma by reducing contents of TGF-β1 and ET-1 in lung tissues.